Tempus AI reported $411.5 million in revenue for the third quarter of 2026, alongside growth in oncology units and Data & Applications revenue, putting the U.S.-listed company’s business performance in focus for investors.
In a Nov. 2 company update, Tempus said oncology unit volume increased 32% and revenue from its Data & Applications segment grew 33%.
Tempus shares, which trade under the ticker TEM, closed at $63.62 on Nov. 18.



